Similar articles

• The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.

  Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M. Fischer JS, et al. Curr Med Res Opin. 2004 Nov;20(11):1703-10. doi: 10.1185/030079904X5526. Curr Med Res Opin. 2004. PMID: 15537471
• The effect of insulin glargine and nutritional model on metabolic control, quality of life and behavior in children and adolescents with type 1 diabetes mellitus.

  Goksen D, Darcan S, Buyukinan M, Köse T, Erermis S, Coker M. Goksen D, et al. Acta Diabetol. 2008 Mar;45(1):47-52. doi: 10.1007/s00592-007-0019-2. Epub 2007 Oct 11. Acta Diabetol. 2008. PMID: 17928940
• Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.

  Vinik AI, Zhang Q. Vinik AI, et al. Diabetes Care. 2007 Apr;30(4):795-800. doi: 10.2337/dc06-1712. Epub 2007 Jan 26. Diabetes Care. 2007. PMID: 17259481 Clinical Trial.
• Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.

  Bradley C, Gilbride CJ. Bradley C, et al. Diabetes Obes Metab. 2008 Jul;10 Suppl 2:50-65. doi: 10.1111/j.1463-1326.2008.00871.x. Diabetes Obes Metab. 2008. PMID: 18577157 Review.
• [Patient satisfaction in diabetes mellitus--measures and results].

  Kohlmann T, Moock J. Kohlmann T, et al. Dtsch Med Wochenschr. 2008 Aug;133 Suppl 4:S120-3; discussion S124-6. doi: 10.1055/s-2008-1081106. Dtsch Med Wochenschr. 2008. PMID: 18686221 Review. German.